Evidence map›Paper›PMID 23086198›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2013

Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Ryan T Bushey, Douglas F Dluzen, Philip Lazarus

Open access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p.The Journal of pharmacology and experimental therapeutics · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Reduction of p53 by knockdown of theCellular and molecular gastroenterology and hepatology · 2016
    Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan T BusheyDepartment of Pharmacology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
Douglas F Dluzen
Philip Lazarus
Pennsylvania State University · US

Funding

UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISKR01DE013158 · NIDCR · UNIVERSITY OF SOUTH FLORIDA · PI LAZARUS, PHILIP · 2000 to 2011
$3.6M
Role of pharmacogenetics on exemestane metabolism and toxicityR01CA164366 · NCI · WASHINGTON STATE UNIVERSITY · PI LAZARUS, PHILIP · 2012 to 2016
$2.4M
NCI NIH HHS R01 CA164366NCI NIH HHS R01-CA164366NIDCR NIH HHS R01 DE013158NIDCR NIH HHS R01-DE13158
6 · The paper itself

Abstract

UDP-glucuronosyltransferase A1 (UGT2A1) is expressed in the lung and exhibits activity against polycyclic aromatic hydrocarbons (PAHs), suggesting UGT2A1 involvement in the local metabolism of PAH tobacco carcinogens. The goal of the present study was to investigate the importance of two additional UGT2A enzymes, UGT2A2 and UGT2A3, in tobacco carcinogen metabolism. Real-time polymerase chain reaction suggested that wild-type UGT2A2 had the highest expression in the breast, followed by trachea > larynx > kidney. A novel splice variant of UGT2A2 lacking exon 3 (termed UGT2A2Δexon3) was investigated, with UGT2A2Δexon3 expression determined to be 25-50% that of wild-type UGT2A2 in all tissues examined. UGT2A3 was determined to be well expressed in the liver and colon, followed by pancreas > kidney > lung > tonsil > trachea > larynx. Cell homogenates prepared from human embryonic kidney (HEK)293 cells overexpressing wild-type UGT2A2 (termed UGT2A2_i1) exhibited glucuronidation activity, as observed by reverse-phase ultra-pressure liquid chromatography, against 1-hydroxy-(OH)-pyrene, 1-naphthol, and hydroxylated benzo(a)pyrene metabolites, whereas homogenates prepared from HEK293 cells overexpressing UGT2A3 only showed activity against simple PAHs like 1-OH-pyrene and 1-naphthol. Activity assays showed the UGT2A2Δexon3 protein (termed UGT2A2_i2) exhibited no detectable glucuronidation activity against all substrates examined; however, coexpression studies suggested that UGT2A2_i2 negatively modulates UGT2A2_i1 activity. Both UGT2A2 and UGT2A3 exhibited no detectable activity against complex PAH proximate carcinogens, tobacco-specific nitrosamines, or heterocyclic amines. These data suggest that, although UGT2A1 is the only UGT2A enzyme active against PAH proximate carcinogens (including PAH diols), both UGTs 2A1 and 2A2 play an important role in the local detoxification of procarcinogenic monohydroxylated PAH metabolites.

Indexed as

Base SequenceCarcinogensDNA PrimersGlucuronosyltransferaseHEK293 CellsHumansIsoenzymesNicotianaReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionCarcinogensDNA PrimersGlucuronosyltransferaseIsoenzymes

Identifiers

PMID23086198
PMCPMC3533432
OpenAlexW2064147706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.